Comment on The Villain of CRISPRparentComments−hmahncke10yYes, exclusively licensing CRISPR on an indication-by-indication basis as a therapeutic itself (as someone below has suggested has already happened by Broad) would be worrisome.
Comments
Yes, exclusively licensing CRISPR on an indication-by-indication basis as a therapeutic itself (as someone below has suggested has already happened by Broad) would be worrisome.